US 11,833,212 B2
Linker peptide for constructing fusion protein
Qiang Li, Shanghai (CN); Yuanli Li, Shanghai (CN); Si Chen, Shanghai (CN); Zhu Wang, Shanghai (CN); Zhao Dong, Shanghai (CN); Zirui Li, Shanghai (CN); Xinlu Ma, Shanghai (CN); Lu Yang, Shanghai (CN); Yongjuan Gao, Shanghai (CN); Yuncheng Zheng, Shanghai (CN); and Naichao Sun, Shanghai (CN)
Assigned to AMPSOURCE BIOPHARMA SHANGHAI INC., Shanghai (CN)
Filed by AMPSOURCE BIOPHARMA SHANGHAI INC., Shanghai (CN)
Filed on Aug. 2, 2021, as Appl. No. 17/391,535.
Application 17/391,535 is a continuation of application No. 16/326,412, granted, now 11,123,438, previously published as PCT/CN2016/106011, filed on Nov. 16, 2016.
Claims priority of application No. 201610692679.4 (CN), filed on Aug. 19, 2016; and application No. 201610694914.1 (CN), filed on Aug. 19, 2016.
Prior Publication US 2022/0105193 A1, Apr. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/65 (2017.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); C07K 14/475 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01); C07K 19/00 (2006.01); C07K 14/54 (2006.01); C07K 14/755 (2006.01); C07K 16/06 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); C12N 15/85 (2006.01)
CPC A61K 47/65 (2017.08) [A61P 3/04 (2018.01); A61P 3/10 (2018.01); C07K 14/475 (2013.01); C07K 14/5418 (2013.01); C07K 14/755 (2013.01); C07K 16/065 (2013.01); C07K 16/2809 (2013.01); C07K 16/2887 (2013.01); C07K 16/468 (2013.01); C07K 19/00 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01)] 20 Claims
 
1. A fusion protein having the structural formula of K1-L-K2 or K2-L-K1, wherein L is a linker peptide between K1 and K2 and L comprises a flexible peptide and a rigid peptide, wherein the flexible peptide comprises one or more flexible units and the rigid peptide comprises one or more rigid units,
wherein the flexible unit has the structural formula of (GS)a(GGS)b(GGGS)c(GGGGS)d (SEQ ID NO: 37), wherein each of a, b, c, and d is an integer equal to or more than 0, and a+b+c+d is selected from 4, 5, 6, and 8;
wherein the rigid unit comprises the amino acid sequence of SEQ ID NO: 1 or a fragment of SEQ ID NO: 1, wherein the fragment comprises the amino acid sequence of SEQ ID NO: 29 or the amino acid sequence of SEQ ID NO: 30; and
wherein K1 or K2 each is selected from a protein, a protein domain, a peptide, an antibody, and an antigen-binding fragment of an antibody.